Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders

(European Society for Medical Oncology) The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumors were reported today at the ESMO 2016 Congress in Copenhagen.